Superworth

Omeros OMER

Drug Manufacturers - General, Healthcare
$17.83
−3.31%
Market cap
$1.3B
PE
11.7×
4y median 11.7×
Forward PE
n/m
not a meaningful number
Price to sales
n/m
one or more of the four quarters through 2026-06-30 missing
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
n/m
one or more of the four quarters through 2026-06-30 missing
Net margin
n/m
one or more of the four quarters through 2026-06-30 missing
Free cash flow yield
−5.3%

Omeros trades at 11.7× trailing earnings.

Charts

Financials

Income statement for OMER, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
n/an/an/an/an/an/a$0$0n/an/a$9.9M$28.5M
Cost of revenuen/an/an/an/an/an/a$0$0n/an/a$587K$798K
Gross profitn/an/an/an/an/an/a$0$0n/an/a$9.3M$27.7M
R&D$31.7M−18%$28.9M+9%$26.8M+9%$45.3M+53%$24.1M−24%$23.3M−19%$23.8M−11%$22M−52%$16M−34%$19.4M−17%$13.4M−44%$13.8M−37%
SG&A$16.4M+35%$10.9M−20%$12.3M+11%$13.8M+23%$11.3M−31%$12.3M+14%$11.1M−9%$10.3M−25%$10.4M−8%$9.6M−22%$13.4M+20%$13.9M+34%
−$48.2M−5%−$39.8M−1%−$39M+9%−$59.2M+45%−$35.4M−27%−$35.7M−10%−$35M−10%−$32.4M−45%−$26.4M−26%−$29.1M−18%−$17.4M−50%$74K
Interest expense$7.9M+61%$7.1M−11%$8.2M+4%$9.2M+16%$4.1M−49%$3.2M−55%$3.7M−56%$15K−100%−$13.4M$8.7M+175%$5.9M+61%$7.6M+50467%
Pre-tax incomen/an/an/an/an/an/a−$37.6M−$25.9Mn/an/a$51.3M$6.7M
n/an/an/an/an/an/a$0$0n/an/a$57K$29K
Net income−$37.8M+116%−$9.1M−$37.2M+10%−$56M+50%−$32.2M−15%−$31.4M+246%−$33.5M−10%−$25.4M−55%−$30.9M−4%$86.5M$56.1M$13.2M
n/an/a−$0.63+17%−$0.97+64%−$0.56−$0.54−$0.58−8%−$0.43−56%−$0.47−16%$1.22$0.62$0.15
n/an/a58.8M−6%57.9M−8%57.9M58M58.1M−1%58.6M+1%66.3M+14%70.8M+22%90.1M+55%89.6M+53%

Gross profit: 35 periods, Q1 FY14 to Q2 FY26: not printed by the filing, worked out from its own lines.

EPS, diluted: 6 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 11 periods, Q4 FY10 to Q4 FY20: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY21 and Q4 FY22: share-days: the 12-month average less the 9-month, weighted by days. 8 periods, Q1 FY24 to Q4 FY25: not printed by the filing, worked out from its own lines.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Omeros' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
OMEROmeros$1.3B11.7×11.7×n/mn/mn/m
ANABAnaptysbio$1.4B10.3×99.3×n/mn/mn/m
AMPHAmphastar Pharmaceuticals$1.1B15.9×20.5×1.6×+1%10.8%
PCRXPacira BioSciences$1.5B104×65.7×1.9×+6%2.0%
PAHCPhibro Animal Health$1.6B15.9×21.5×1.0×+17%6.6%
ANIPANI Pharmaceuticals$1.6B15.0×57.5×1.7×+31%11.1%
ABUSArbutus Biopharma$791.4M5.1×5.6×4.4×n/m84.2%
COLLCollegium Pharmaceutical$770.9M19.1×19.1×1.0×+14%5.9%
HRMYHarmony Biosciences$2.2B12.3×13.8×2.3×+24%18.9%
PBHPrestige Consumer Healthcare$2.4B13.9×15.3×2.1×−1%15.6%
ZVRAZevra Therapeutics$599.8M10.9×12.2×4.4×+119%42.8%
Peer median$1.4B14.5×19.8×1.9×+16%11.1%

More on Omeros

Each number over time

Where it ranks

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .